Find policies, billing codes, payers, states, and providers
Biomarker Testing for Autoimmune Rheumatic Disease
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage and limits for serologic biomarker testing (ANA, ENA, RF, anti-CCP, anti-dsDNA, select disease-specific antibodies and biomarker panels) used in evaluation and monitoring of systemic autoimmune rheumatic diseases for Oscar Health members.
No material clinical or coverage changes in this revision.
Coverage Criteria — When Testing Is Medically Necessary
inv-01: Medically necessary testing — Covered when specific clinical conditions are met as follows:
Covered when ALL of the following clinical conditions are met:
inv-02: Not medically necessary / Not covered testing — The following do not meet criteria:
The following do not meet criteria (any of the following may be considered not medically necessary):
inv-03: Reflex testing recommendations — Guidance and evidence summaries for test use
Guidance and evidence-based reflex testing recommendations to guide appropriate downstream testing:
inv-04: Analytical validity and assay choice — Selection of initial ANA assay
Considerations for selection of the initial ANA assay and follow-up testing:
inv-05: Proprietary test evidence — Proprietary multianalyte and molecular tests
Summary of proprietary multianalyte and molecular test claims and observed clinical findings reported in the literature:
inv-06: Evidence summaries for multi-biomarker tests — Reported performance characteristics and literature evidence
Reported performance characteristics, study findings, and limitations from the evidence base for multi‑biomarker tests:
inv-07: SLICC criteria (SLE) — Classification items used in clinical/immunologic classification
SLICC classification items used in clinical and immunologic assessment of suspected SLE:
inv-08: RA diagnostic and monitoring guidance — Guideline-based recommendations relevant to RA diagnosis and testing:
Guideline-based recommendations relevant to RA diagnosis and testing (selection and monitoring):
Serum biomarker panel testing that reports proprietary algorithms or index scores to diagnose, prognose, or monitor systemic lupus erythematosus (SLE) or other connective tissue diseases (CTDs) is not supported by sufficient published evidence. Examples cited in the policy include AVISE CTD, AVISE SLE Monitor, AVISE SLE Prognostic, aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile, and tissue‑specific marker panels; such tests DO NOT MEET CRITERIA for routine coverage. This determination reflects the policy's conclusion that available literature does not confirm these panels are required and beneficial for patient diagnosis or management.
Providers should rely on established serologic tests (ANA screening, ENA sub‑specificities, anti‑dsDNA, RF, anti‑CCP) and documented clinical correlation when evaluating suspected SLE/CTD rather than ordering proprietary multi‑analyte panels as a first‑line diagnostic or monitoring strategy.
Repeat antinuclear antibody (ANA) testing after an initially negative ANA has limited clinical utility and high cost. A cited study found that among patients who repeated ANA testing after a negative result, only a small proportion converted to positive and such conversions did not change diagnosis; the authors concluded that ‘repeat ANA testing after a negative result has low utility.’ The policy therefore discourages routine repeat ANA assays without a new or worsening clinical indication.
If new or more severe signs or symptoms of autoimmune disease develop, the policy permits repeat ANA testing per the specified coverage thresholds (see medically necessary testing criteria); absent new clinical indications, repeat testing following a negative ANA is unlikely to be medically necessary.
Clinical guidelines and Choosing Wisely recommendations advise against ordering ANA subserologies or broad autoantibody panels in the absence of a positive ANA and compatible clinical suspicion. The policy echoes this guidance: do not order ENA/subserology panels without a positive ANA and documented clinical signs of immune‑mediated disease, and payers may require documentation of a positive ANA and supporting clinical findings before authorizing reflex or panel testing.
When ANA screening is positive, reflex testing for specific ENA antibodies and anti‑dsDNA—guided by HEp‑2 pattern and titer—may be indicated and should be selected based on clinical context and established reflex algorithms.
If this policy conflicts with any applicable government coverage directive (for example, a Medicare National Coverage Determination or Local Coverage Determination, or a state Medicaid policy), the applicable government policy will take precedence and will be used to make coverage determinations. Providers and reviewers should consult the current Medicare Coverage Database or the relevant state Medicaid resources for up‑to‑date government guidance when making determinations.
This section cites evidence‑based scientific references supporting the policy’s clinical summaries and rationale. Representative references include peer‑reviewed evaluations of ANA assay methods and studies of multianalyte panels and MBDA/PrismRA validation and utility (for example, Alsaed et al. 2021; Wallace et al. 2019; Clarke et al. 2020; Mellors et al. 2020). These references are provided to inform medical necessity review and clinical interpretation of test performance and limitations.
The bibliography entries listed in chunks 72–79 supply the underlying literature referenced elsewhere in the policy; this section does not itself state coverage exclusions but serves as the supporting evidence base for the policy statements.
The policy identifies several specific uses that are discouraged: ANA or ENA testing in asymptomatic individuals (including during routine wellness visits), use of ANA titers for routine monitoring of disease activity, and ordering specific autoantibody tests or broad autoantibody panels without a positive ANA and compatible clinical findings. These practices DO NOT MEET CRITERIA and may be subject to denial if submitted without appropriate documentation of signs or symptoms.
Guideline recommendations cited (ACR / Choosing Wisely) state: “Do not test antinuclear antibody (ANA) subserologies without a positive ANA and clinical suspicion of immune‑mediated disease.”
Routine repeat ANA testing after an initial negative result generally lacks clinical utility and is unlikely to change diagnosis when performed without new clinical findings. A large observational analysis concluded that repeat negative→positive conversions were uncommon and did not alter diagnosis, leading the authors to state that ‘repeat ANA testing after a negative result has low utility’. Accordingly, repeat ANA testing without new or evolving signs or symptoms may be considered not medically necessary.
Per the policy, repeat ANA testing is permitted only when clinically justified (for example, when new or more severe symptoms arise), consistent with the specified coverage thresholds for additional testing.
Current RA management guidelines and task‑force reports do not recommend routine use of multi‑biomarker panels (for example, MBDA/Vectra DA or PrismRA) for diagnosis or routine disease‑management decisions. The 2021 ACR guidance and subsequent international task force documents reviewed in the policy do not endorse these proprietary multi‑biomarker tests as standard diagnostic or monitoring tools for RA.
Additionally, randomized trial data have raised concerns about responsiveness of some multi‑biomarker scores (for example, MBDA changes below the minimally important difference in a randomized RA trial), and the policy therefore does not support routine clinical use of these tests for RA diagnosis or management absent stronger evidence.
Some chunks of the evidence section compile citations and reference listings without making explicit 'not medically necessary' determinations themselves. These bibliographic entries support the policy’s clinical conclusions elsewhere in the document but do not by themselves state coverage exclusions or determinations.
Reviewers should rely on the policy’s coverage and not‑medically‑necessary sections for coverage stance; the cited literature is provided to substantiate those policy decisions.
Procedure and Proprietary Codes
| 86038 | Antinuclear antibodies (ANA). |
| 86039 | Antinuclear antibodies (ANA); titer. |
| 86200 | Cyclic citrullinated peptide (CCP), antibody. |
| 86225 | Deoxyribonucleic acid (DNA) antibody; native or double stranded. |
| 86235 | Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody. |
| 86430 | Rheumatoid factor; qualitative. |
| 86431 | Rheumatoid factor; quantitative. |
| 0039U | Lab/Manufacturer: University of Washington/Bio-Rad. Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, algorithm reported with a risk score (Proprietary test: SLE-key® Rule Out). |
Provider Actions, Prior Authorization & Documentation
Prior authorization when medical necessity review applies
Prior authorization is required when services are subject to medical necessity review per member benefits and authorization guidelines; this policy is used to guide medical necessity determinations for ANA/ENA, RF/anti-CCP, anti-dsDNA and select antibodies.
- Authorization requirement depends on member benefit and payer-specific procedures.
- Services must meet medical necessity and coding/billing guidelines at time of request.
Prior authorization may be required for proprietary/multianalyte tests
Proprietary multianalyte/molecular signature tests (examples: AVISE Lupus/CTD, PrismRA, Vectra DA, aiSLE DX) are discussed as diagnostic/prognostic/monitoring tools and may require prior authorization where payer rules restrict coverage of LDTs or proprietary panels.
- AVISE tests use a two‑tiered method and CB‑CAPs; AVISE Lupus is described as “an ideal test for ANA positive patients with a clinical suspicion of lupus.”
- PrismRA (MSRC) predicts TNFi non‑response using a 23‑feature RNA signature.
- Vectra DA and aiSLE DX are listed as proprietary MBDA/DA tests.
ANA screen required before subserologies/panels
Do not order ANA subserologies or broad autoantibody panels without a positive ANA screen and clinical suspicion; payers may require documentation of a positive ANA and clinical indication prior to authorizing reflex or panel testing.
- ACR/Choosing Wisely recommendation: “Do not test antinuclear antibody (ANA) subserologies without a positive ANA and clinical suspicion of immune‑mediated disease.”
- Policy states ENA panel testing meets criteria only for individuals with an abnormal, raised ANA titer and clinical correlation.
Procedure codes listed — include when requesting authorization/billing
Reportable CPT/PLA codes for ANA/ENA/RF/anti‑CCP/anti‑dsDNA and listed proprietary tests are included in the policy and may be used when requesting authorization or submitting claims; follow payer-specific prior‑auth procedures.
No universal prior‑auth workflow specified in policy text
No additional payer‑level prior authorization rules are specified within these chunks; authorization practice remains dependent on member benefits and payer procedures.
- Publication history and policy applicability are provided, but no explicit universal prior‑auth workflow is defined in the cited sections.
Drug step therapy context — no test‑based mandates specified
csDMARDs are first‑line for RA and bDMARDs (including TNFis) are used when csDMARDs fail; the policy does not establish drug step‑therapy mandates for these agents.
- Background notes describe standard csDMARD → bDMARD sequencing but do not impose test‑based step therapy requirements.
PrismRA may inform biologic selection but does not mandate step therapy
PrismRA predicts TNF‑inhibitor non‑response and could be used to inform biologic selection prior to initiating TNFi therapy; implementation may interact with but does not create an explicit payer step‑therapy requirement.
- PrismRA uses a 23‑feature MSRC integrating RNA sequencing and clinical features to predict TNFi non‑response.
- CERTAIN and NETWORK‑004 validations report PPV 89.7%, specificity 86.8%, sensitivity 50%.
No explicit step‑therapy mandates for MBDA/PrismRA in guidelines
Clinical RA management guidelines and the policy text do not specify step‑therapy requirements for MBDA (Vectra DA) or PrismRA; no explicit testing‑based step therapy is recommended.
- 2021 ACR RA guideline and other task forces do not recommend routine use of multi‑biomarker tests for diagnosis or management.
- Policy statements note absence of explicit step‑therapy testing rules in the guideline extracts.
Testing sequencing in RA workup (NICE guidance)
NICE guidance implies sequencing in RA workup: refer patients with suspected persistent synovitis to specialists and test RF; consider anti‑CCP when RF is negative and combination therapy is considered.
- NICE: “Offer to test for rheumatoid factor in people with suspected rheumatoid arthritis who have synovitis.”
- “Consider measuring anti‑CCP… if they are negative for RF and combination therapy is being considered.”
No step‑therapy rules provided in cited studies
No formal step‑therapy rules are specified in the cited literature; studies cited describe evaluation and validation of multibiomarker panels and MAP tests but do not define payer step therapy.
- Evidence references and clinical validation studies for MAP/MBDA/PrismRA are listed, but no step‑therapy policies are provided.
Required documentation with clinical signs/symptoms and benefit verification
Providers must submit clinical documentation demonstrating signs/symptoms, clinical correlation, and benefit coverage at time of request; insufficient documentation may result in denial.
- Documentation should show active signs/symptoms consistent with the requested test and member benefit eligibility at time of request.
- Coding should follow standard industry coding/billing guidelines to avoid claim denial.
If ANA positive — perform reflex anti‑dsDNA/ENA guided by HEp‑2 pattern/titre
If an ANA screen is positive, reflex testing for anti‑dsDNA and ENA sub‑specificities is recommended and the reflex choices should be guided by HEp‑2 IIF pattern and titre (see Table 1 for pattern→reflex mappings).
- Table 1: for nuclear homogeneous ≥1:160 reflex = anti‑dsDNA and ENA; centromere pattern requires anti‑CENP‑B only in dubious/low titre cases.
- Reflex testing aims to identify sub‑specificities tied to distinct ANA patterns.
Document classification criteria entry status and relevant clinical findings
Document presence or absence of classification entry and clinical criteria (for example ANA at HEp‑2 titer ≥1:80 per EULAR/ACR and SLICC clinical/immunologic items) when ordering or interpreting SLE‑related biomarker testing.
- EULAR/ACR: ANA at titer ≥1:80 on HEp‑2 cells is an entry criterion for SLE.
- SLICC criteria list required clinical and immunologic items (including ANA, anti‑dsDNA, anti‑Sm, low complement) that should be documented.
Include SLICC‑consistent clinical justification and evidence references
When ordering lupus‑related testing, include clinical justification aligned with SLICC/ACR/EULAR criteria (list clinical and immunologic SLICC items) and cite supporting scientific evidence when available.
- Policy requires clinical criteria consistent with SLICC when testing for lupus and recommends including relevant diagnostic rationale with CPT/proprietary test requests.
- Evidence references (chunks 72–74) are provided to support medical necessity documentation.
Denial risk: testing without symptoms or for proprietary panels
Claims for ANA/ENA testing without signs/symptoms of autoimmune disease, ANA/ENA ordered during wellness visits in asymptomatic individuals, and proprietary multianalyte panel testing for SLE/CTD risk denial.
- Policy explicitly states ANA/ENA testing in asymptomatic individuals and testing during wellness exams does not meet criteria.
- Serum biomarker panels with proprietary algorithms (eg, AVISE CTD, AVISE SLE Monitor, aisle® DX) do not meet criteria due to insufficient evidence.
Denial risk: repeat ANA after negative result without new indication
Repeat ANA testing after an initial negative ANA has low utility and may be denied without a new clinical indication — repeat testing showed low yield and increased cost in cited studies.
- Yeo et al. (2020) found only 19% of repeated ANA tests after a prior negative converted to positive and did not change diagnosis; policy notes repeats lack utility.
- Policy allows up to two additional ANA/RF tests per lifetime only if new or more severe signs/symptoms develop.
Denial risk: ANA subserologies without a positive ANA
Ordering ANA subserologies or autoantibody panels without a positive ANA and clinical suspicion is discouraged and may be questioned by guideline‑based review and payer authorization.
- ACR/Choosing Wisely: “Do not test antinuclear antibody (ANA) subserologies without a positive ANA and clinical suspicion.”
- Policy states specific antibody testing outside a positive ANA generally does not meet criteria.
Government policy precedence may affect authorization/denial
Coverage determinations will defer to applicable government policies (LCDs/NCDs); if governmental policy conflicts with this policy, the government policy will control and may affect authorization/denial.
- Policy instructs to consult Medicare/Medicaid coverage databases for the most up‑to‑date government policies.
- Providers should verify state Medicaid or LCD/NCD provisions that may supersede this policy.
Background and Scope
Systemic autoimmune rheumatic diseases (SARDs) represent a heterogeneous group that includes systemic lupus erythematosus (SLE), Sjögren's syndrome, mixed connective tissue disease, systemic sclerosis, idiopathic inflammatory myopathies, and rheumatoid arthritis. These disorders are characterized by autoantibodies and immune‑mediated tissue injury, and serologic testing (ANA by IIF on HEp‑2 cells, ENA sub‑specificities, anti‑dsDNA, RF, anti‑CCP, and selected disease‑specific antibodies) is commonly used in evaluation and classification.
The policy emphasizes that ANA by indirect immunofluorescence remains the reference screening test with high sensitivity but limited specificity, and that disease‑specific antibodies or targeted reflex testing should be performed only with appropriate clinical correlation. Proprietary multianalyte panels and other multi‑biomarker assays lack sufficient published evidence to support routine diagnostic, prognostic, or monitoring use across SARDs, which underpins the policy’s restrictive coverage stance for such panels.
Definitions and Test Descriptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.